Bharat Immunologicals And Biologicals Corporation Profile
Key Indicators
- Authorised Capital ₹ 51.00 Cr
- Paid Up Capital ₹ 43.18 Cr
- Company Age 35 Year, 10 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 145.40 Cr
- Satisfied Charges ₹ 31.80 Cr
- Revenue Growth -8.65%
- Profit Growth 51.67%
- Ebitda 76.12%
- Net Worth 209.49%
- Total Assets 104.57%
About Bharat Immunologicals And Biologicals Corporation
Bharat Immunologicals And Biologicals Corporation Limited (BIABCL) is a leading Public Limited Union Government Company incorporated in India on 10 March 1989 and has a history of 35 years and ten months. Its registered office is in Bulandshahr, Uttar Pradesh, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 524663.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 51.00 Cr and a paid-up capital of Rs 43.18 Cr.
The company currently has active open charges totaling ₹145.40 Cr. The company has closed loans amounting to ₹31.80 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Bharat Immunologicals And Biologicals Corporation Limited India is Sandip Lal as COMPANY SECRETARY. Mohd Aslam, Pankaj Kumar, Sudhanshu Vrati, and Four other members serve as directors at the Company.
Company Details
-
Location
Bulandshahr, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
L24232UP1989GOI010542
-
Company No.
010542
-
Stock Symbol
BSE : 524663
-
Company Classification
Public Limited Union Government Company
-
Incorporation Date
10 Mar 1989
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Listed
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Bharat Immunologicals And Biologicals Corporation?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sandip Lal
|
Company Secretary | 03-Sep-2007 | Current |
|
Dhananjay Tiwary
|
Managing Director | 18-Sep-2023 | Current |
Board Members (6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Sudhanshu Vrati
|
Director | 01-Nov-2016 | Current |
|
Mohd Aslam
|
Director | 01-Nov-2016 | Current |
|
Pankaj Kumar
|
Director | 01-Feb-2022 | Current |
|
Alka Sharma
|
Director | 01-Nov-2016 | Current |
|
Madhu Dikshit
|
Director | 21-Jun-2019 | Current |
|
Yogendra Gupta
|
Director | 26-Oct-2010 | Current |
Financial Performance of Bharat Immunologicals And Biologicals Corporation.
Bharat Immunologicals And Biologicals Corporation Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 8.65% decrease. The company also saw a substantial improvement in profitability, with a 51.67% increase in profit. The company's net worth Soared by an impressive increase of 209.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bharat Immunologicals And Biologicals Corporation?
In 2022, Bharat Immunologicals And Biologicals Corporation had a promoter holding of 59.25% and a public holding of 40.73%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Foundation For Disease Elimination And Control Of IndiaYogendra Gupta is a mutual person
-
Sicuremi Healthcare Technologies Private LimitedYogendra Gupta is a mutual person
-
India Pesticides Limited.Madhu Dikshit is a mutual person
-
Cliantha Research LimitedYogendra Gupta is a mutual person
-
Indian Vaccines Corporation LimitedPankaj Kumar and Alka Sharma are mutual person
-
Vatyka Health Vision Llp
Yogendra Gupta is a mutual person
Charges (Loans)
₹145.40 Cr
₹31.80 Cr
Charges Breakdown by Lending Institutions
- Canara Bank : 133.00 Cr
- Industrial Development Bank Of India : 10.10 Cr
- Industrial Credit & Investment Corporation Of India Ltd. : 0.95 Cr
- The State Bank Of India : 0.80 Cr
- State Bank Of Hyderabad : 0.55 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 10 Feb 2012 | Canara Bank | ₹133.00 Cr | Open |
| 26 May 1993 | Industrial Credit & Investment Corporation Of India Ltd. | ₹9.50 M | Open |
| 17 Sep 1992 | The State Bank Of India | ₹8.00 M | Open |
| 24 Mar 1992 | State Bank Of Hyderabad | ₹5.50 M | Open |
| 03 May 1991 | Industrial Development Bank Of India | ₹7.50 Cr | Open |
How Many Employees Work at Bharat Immunologicals And Biologicals Corporation?
Unlock and access historical data on people associated with Bharat Immunologicals And Biologicals Corporation, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bharat Immunologicals And Biologicals Corporation, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bharat Immunologicals And Biologicals Corporation's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
